Plus Therapeutics (NASDAQ:CNSY) Stock Rating Raised to Hold at Zacks Research

Plus Therapeutics (NASDAQ:CNSY) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Plus Therapeutics has an average rating of “Reduce”.

Plus Therapeutics Stock Performance

CNSY stock traded up $0.18 during trading on Thursday, hitting $0.95. The company had a trading volume of 8,046,110 shares, compared to its average volume of 1,810,277. The company has a 50-day simple moving average of $1.70. Plus Therapeutics has a 12 month low of $0.43 and a 12 month high of $18.89. The company has a market cap of $7.21 million, a PE ratio of -0.28 and a beta of 1.49.

Plus Therapeutics (NASDAQ:CNSY) last announced its quarterly earnings data on Friday, November 13th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16). The firm had revenue of $0.72 million during the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. Equities research analysts predict that Plus Therapeutics will post -4.40 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.